Samsung Biologics launches organoid platform to boost early-stage drug discovery
Organoids are three-dimensional cell culture systems engineered to closely replicate the structure and function of human organs. Due to their high physiological relevance, organoids are rapidly emerging as a next-generation research model in drug development. They offer clinically meaningful insights into drug responses, making them valuable tools for lead compound selection, biomarker discovery and efficacy prediction.
'The latest service launch reflects our unwavering commitment to driving innovation by improving drug success rates and creating new possibilities in personalized medicine,' said John Rim, CEO and president of Samsung Biologics.
'The addition of research services is a significant move for us to create added value for clients by supporting the drug life cycle from start to finish with thorough therapeutic analysis.'
Samsung Organoids will enable precision screening to predict patient-specific drug responses, streamline preclinical development and accelerate timelines for investigational new drug filings. The platform uses data-driven analysis to assess the characteristics and mechanisms of drug candidates, offering multi-modal insights that enhance decision-making.
Through the expansion, Samsung Biologics broadens its service portfolio to include preclinical research, covering the full spectrum from target discovery and lead identification to preclinical studies and clinical trial planning. By leveraging its expertise in drug development and manufacturing, the company aims to help clients overcome early-stage development hurdles and improve clinical outcomes.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
23-07-2025
- Korea Herald
Samsung Biologics reports second quarter 2025 financial results
INCHEON, South Korea, July 23, 2025 /PRNewswire/ -- Samsung Biologics (KRX: a leading contract development and manufacturing organization (CDMO), today announced its financial results for the second quarter of fiscal year 2025. "Our second quarter results demonstrate continued strong momentum across our business," said John Rim, CEO and President of Samsung Biologics. "With Plant 5 now fully operational, we are leveraging our manufacturing expertise and expanded capacity to deliver seamless, end-to-end CDMO services at scale. We have broadened our portfolio with advancements in antibody-drug conjugates (ADCs) and the launch of research services, Samsung Organoids, further reinforcing our ability to offer a wider range of innovative solutions to clients. Additionally, we are redefining digitalization in biomanufacturing, harnessing advanced digital tools to deliver greater transparency, speed, and value—setting new standards in the industry. These strategic initiatives will continue to strengthen our ability to accelerate client pipelines, while fostering enduring partnerships grounded in quality and operational excellence." SECOND QUARTER 2025 RESULTS Samsung Biologics posted consolidated revenue of KRW 1,289.9 billion and operating profit of KRW 475.6 billion in the second quarter of 2025. On a standalone basis, the company reported revenue of KRW 1,014.2 billion and operating profit of KRW 477.0 billion. The growth was buoyed by the full utilization of Plants 1 through 3 and the continued ramp-up of Plant 4. In the first half of 2025, standalone revenue surpassed KRW 2 trillion, reflecting consistent momentum across all manufacturing plants. Sales contract volume in the first half reached USD 2.4 billion, bringing up the cumulative value to USD 18.7 billion. BUSINESS UPDATES In April, Samsung Biologics added 180 kL of capacity with Plant 5 to better meet clients' manufacturing needs. The facility, equipped with advanced automation and digital systems, integrates best practices and features from existing plants to ensure consistent operations and the highest quality standards. The company also broadened its service offering with the launch of research services, Samsung Organoids, which utilizes patient-derived organoids to support drug discovery and development. Samsung Organoids enables precision screening to predict patient-specific drug responses and provides clients with multi-modal insights to effectively support early-stage decision making. In May, Samsung Biologics announced plans to spin off its wholly-owned subsidiary, Samsung Bioepis. Through the financial and legal separation, the company will focus on strengthening its core capabilities as a pure-play CDMO, enhancing customer satisfaction and proactively responding to the industry's greater demands to ultimately maximize corporate value and sustainable growth potential. On the sustainability front, the company released its 2025 ESG report in June, outlining progress in areas including enhanced disclosure standards, an accelerated path to net-zero, and TNFD-aligned risk management. As part of its decarbonization efforts, Samsung Biologics achieved a 24% reduction in greenhouse gas emissions in 2024 compared to the previous year and increased its renewable energy use to 29% of total electricity consumption. The company also signed an additional solar Power Purchase Agreement to further support its energy transition. Beyond operations, Samsung Biologics is actively engaged in collaborative efforts through the Sustainable Market Initiative to decarbonize healthcare supply chains and promote global environmental responsibility. About Samsung Biologics Samsung Biologics (KRX: is a leading contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing. With a combined biomanufacturing capacity of 784 kL across five plants, Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics. Samsung Biologics operates a global network with facilities and offices in Korea, the U.S., and Japan. Samsung Biologics America supports clients based in the U.S. and Europe, while its Tokyo sales office serves the APAC region. Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. The company is committed to the on-time, in-full delivery of safe, high-quality products, as well as making sustainable business decisions for the betterment of society and global health.
Korea Herald
11-07-2025
- Korea Herald
Samyang's hot streak: Global Buldak craze sends stock to record high
Shares of Samyang Foods topped the 1.5 million won ($1,090) mark, rising nearly 50 percent in just two months, as investors bet on the enduring global popularity of its hot chicken noodles, Buldak. On Thursday, the stock hit an intraday high of 1,502,000 won before closing at 1,494,000 won on the benchmark Kospi. It opened at 1,503,000 won on Friday and briefly notched a new all-time high of 1,535,000 won. As of 11 a.m. Friday, shares had eased to 1,470,000 won. The rally extends a blistering run for Samyang, which passed the 1 million won mark on May 12, a milestone that places the food maker alongside Samsung Biologics as a company with seven-figure share prices. Analysts credit the surge to expectations of strong quarterly earnings and increased production capacity. "The company's new facility will drive earnings growth as Buldak production scales up exports to the US and Europe from the third quarter," an analyst from Korea Investment & Securities noted. Sales growth was limited in the first quarter due to supply constraints in the US and Europe, the analyst added, suggesting a sharp pickup ahead. In June, Samyang's new plant in Miryang, South Gyeongsang Province, came online to supply the US and European markets. The noodle maker currently produces all of its products in Korea but is building its first overseas plant in China, slated for completion in 2027. A Kyobo Securities analyst also offered an upbeat outlook: 'Given Samyang's strong global recognition, there appears to be ample room for further upward revisions in its valuation.' Last year, Samyang's annual sales rose 45 percent to 1.73 trillion won, with operating profit soaring 133 percent to 344.2 billion won. Overseas sales reached a record 1.33 trillion won, making up nearly 80 percent of total revenue. In the US, sales doubled to $280 million; sales in China surged 75 percent to $290 million. According to financial information provider FN Guide, Samyang Foods' operating profit for the first half of this year is projected to jump 55.4 percent on-year to 263.5 billion won, with revenue projected to rise 32.2 percent to 1.07 trillion won.
Korea Herald
25-06-2025
- Korea Herald
Seoul shares open lower despite overnight Wall Street gains
South Korean stocks opened slightly lower Wednesday despite overnight US stocks gains boosted by eased Middle Eastern tensions and hopes of an early interest rate cut. The benchmark Korea Composite Stock Price Index shed 1.31 points, or 0.04 percent, to 3,102.33 in the first 15 minutes of trading. Overnight, Wall Street gained ground as investors focused on easing tensions in the Middle East following the ceasefire between Israel and Iran, and the possibility of an early interest rate cut raised by US Federal Reserve Chair Jerome Powell during a testimony at the U.S Congress. In Seoul, overall losses were led by bio and battery shares. Top bio company Samsung Biologics fell 1 percent, and leading battery manufacturer LG Energy Solution lost 1.5 percent. Financial and internet portal shares also retreated. Kookmin Financial dropped 2.14 percent, and top portal operator Naver slumped 3.1 percent. In contrast, semiconductor shares continued their upward momentum from the previous session. Market heavyweight Samsung Electronics and chip rival SK hynix rose 0.5 percent and 2.69 percent, respectively. Kakao Pay also surged 14.18 percent on hopes that the online lender could benefit from the government's push to adopt won-pegged stablecoins. The local currency was trading at 1,357.25 won against the greenback at 9:15 a.m., up 2.95 won from the previous session. (Yonhap)
